TGF-beta RI Overview
Molecule Name
Transforming growth factor beta receptor 1
Synonyms
TGFR-1, ALK-5, TGF-beta receptor type-1, Activin receptor-like kinase 5
Drug Development Progress
Drugs in Clinical Trials7
Approved Drugs0
Highest Development StagePhase 3 Clinical
Target Synonym
EC 2.7.11，TGF-beta type I receptor，Serine/threonine-protein kinase receptor R4，TGFBR1，Activin A receptor type II-like protein kinase of 53kD，Transforming Growth Factor Beta Receptor 1，Transforming Growth Factor-Beta Receptor Type I，Activin A Receptor Type II-Like Kinase， 53kDa，Activin Receptor-Like Kinase 5，TGFR-1，ALK-5，ALK5，SKR4，Mutant Transforming Growth Factor Beta Receptor I，TGF-Beta Receptor Type-1，TGF-Beta Receptor Type I，EC 2.7.11.30，ACVRLK4，LDS1A，LDS2A，AAT5，LDS1，TBRI，ESS1，MSSE，TbetaR-I，Transforming Growth Factor Beta Receptor I，Multiple Self-Healing Squamous Epithelioma，TBR-I，Receptor， Transforming Growth Factor-beta Type I，EC:2.7.11.30
Background
TGF type I receptor also called the activin receptor-like kinase 5 (ALK5) and involved in TGF signaling. TGFβ signaling is mediated by the interaction of TGFβ ligands (TGFβ 1, 2 or 3) with cell surface receptors, the TGF type I, type II and type III receptors. Signaling is initiated by binding of TGF to the TGF type II receptor forming a ligand-receptor complex which interacts with the TGF type I receptor.
TGF-beta RI Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Galunisertib | LY-2157299 | Phase 3 Clinical | Eli Lilly And Company | Amyotrophic Lateral Sclerosis; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Glioma; Liver Neoplasms; Metastatic breast cancer; Myelodysplastic Syndromes; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| GF-101 | GFH-018; GF-101; GFH018 | Phase 2 Clinical | Genfleet Therapeutics (Shanghai) Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Liver Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| Tosposertib phosphate | TU-2218; NCE401; NCE-401 | Phase 2 Clinical | TiumBio Co Ltd | Idiopathic Pulmonary Fibrosis; Solid tumours | Details |
| Ontunisertib | ORG-129; AGMB-129 | Phase 2 Clinical | Origo Biopharma Sociedad Litmitada | Crohn Disease | Details |
| TRK-250 | TRK-250; BNC-1021 | Phase 1 Clinical | Bonac Corp | Idiopathic Pulmonary Fibrosis | Details |
| Oxinseti | SH-3051 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Liver Neoplasms; Solid tumours | Details |
| AGMB-447 | AGMB-447; ORG-447 | Phase 1 Clinical | AgomAb Therapeutics NV | Idiopathic Pulmonary Fibrosis | Details |